吉西他滨与生理盐水膀胱灌注预防低级别非肌层浸润性膀胱癌复发的随机试验
SWOG S0337 在美国 23 个中心随机双盲比较经尿道膀胱肿瘤电切术(TURBT)后即刻膀胱灌注吉西他滨(2 g/100 mL 生理盐水)与生理盐水对疑似低级别非肌层浸润性尿路上皮癌复发的影响。意向性分析显示吉西他滨组 4 年复发估计为 35%,盐水组为 47%,复发风险显著降低。
要点
- TURBT 后即刻灌注吉西他滨较生理盐水显著降低复发风险(HR 0.66;95%CI 0.48-0.90;P<.001)。
- 确诊低级别非肌层浸润性尿路上皮癌亚组复发风险降低更明显(HR 0.53;95%CI 0.35-0.81;P=.001)。
- 未观察到 4 级或 5 级不良事件,3 级及以下不良事件无显著差异。
核心结论
- 在疑似低级别非肌层浸润性尿路上皮癌患者中,TURBT 后即刻膀胱灌注吉西他滨较生理盐水显著降低中位 4.0 年内的复发风险。
- 该结果支持使用这一疗法,但仍需进一步研究将吉西他滨与其他膀胱灌注药物比较。
研究设计与样本
- 随机双盲临床试验,在美国 23 个中心开展。
- 2008 年 1 月 23 日至 2012 年 8 月 14 日入组,按膀胱镜表现疑似低级别非肌层浸润性尿路上皮癌、且 18 个月内无高级别或不超过 2 次低级别尿路上皮癌发作的患者。
- 随机分配吉西他滨组 201 例(2 g 溶于 100 mL 生理盐水)与生理盐水组 205 例(100 mL),TURBT 后即刻灌注 1 小时。
- 共 406 例符合条件患者随机(中位年龄 66 岁,84.7% 为男性),383 例完成试验;随访每 3 个月行膀胱镜与细胞学检查持续 2 年,之后每半年 1 次持续 2 年,末次随访 2016 年 8 月 14 日。
主要发现
- 意向性分析中,吉西他滨组 201 例中 67 例复发(4 年估计 35%),盐水组 205 例中 91 例复发(4 年估计 47%),风险比 0.66(95%CI 0.48-0.90),单侧对数秩检验 P<.001。
- 接受 TURBT 及药物灌注的低级别非肌层浸润性尿路上皮癌 215 例中,吉西他滨组 102 例中 34 例复发(4 年估计 34%),盐水组 113 例中 59 例复发(4 年估计 54%),风险比 0.53(95%CI 0.35-0.81),单侧对数秩检验 P=.001。
- 15 例肿瘤进展至肌层浸润(吉西他滨组 5 例,盐水组 10 例;单侧对数秩检验 P=.22)。
- 42 例任何原因死亡(吉西他滨组 17 例,盐水组 25 例;单侧对数秩检验 P=.12)。
- 无 4 级或 5 级不良事件,3 级及以下不良事件无显著差异。
关键数值与推荐
- 吉西他滨剂量为 2 g 溶于 100 mL 生理盐水,TURBT 后即刻膀胱灌注 1 小时;对照组灌注生理盐水 100 mL。
- 主要终点为复发时间;次要终点为肌层浸润时间与任何原因死亡。
临床怎么用
- 对疑似低级别非肌层浸润性尿路上皮癌患者,可考虑 TURBT 后即刻膀胱灌注吉西他滨以降低复发风险。
- 该疗法安全性可接受,未观察到 4 级或 5 级不良事件。
- 与其他膀胱灌注药物的比较尚需进一步研究,临床选择时应结合患者具体情况。
局限性
- 原文摘要未报告与本试验相关的其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT). OBJECTIVE: To determine whether immediate post-TURBT intravesical instillation of gemcitabine reduces recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared with saline. DESIGN, SETTING, AND PARTICIPANTS: Randomized double-blind clinical trial conducted at 23 US centers. Patients with suspected low-grade non-muscle-invasive urothelial cancer based on cystoscopic appearance without any high-grade or without more than 2 low-grade urothelial cancer episodes within 18 months before index TURBT were enrolled between January 23, 2008, and August 14, 2012, and followed up every 3 months with cystoscopy and cytology for 2 years and then semiannually for 2 years. Patients were monitored for tumor recurrence, progression to muscle invasion, survival, and toxic effects. The final date of follow-up was August 14, 2016. INTERVENTIONS: Participants were randomly assigned to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline) (n = 201) or saline (100 mL) (n = 205) for 1 hour immediately following TURBT. MAIN OUTCOMES AND MEASURES: The primary outcome was time to recurrence of cancer. Secondary end points were time to muscle invasion and death due to any cause. RESULTS: Among 406 randomized eligible patients (median age, 66 years; 84.7% men), 383 completed the trial. In the intention-to-treat analysis, 67 of 201 patients (4-year estimate, 35%) in the gemcitabine group and 91 of 205 patients (4-year estimate, 47%) in the saline group had cancer recurrence within 4.0 years (hazard ratio, 0.66; 95% CI, 0.48-0.90; P<.001 by 1-sided log-rank test for time to recurrence). Among the 215 patients with low-grade non-muscle-invasive urothelial cancer who underwent TURBT and drug instillation, 34 of 102 patients (4-year estimate, 34%) in the gemcitabine group and 59 of 113 patients (4-year estimate, 54%) in the saline group had cancer recurrence (hazard ratio, 0.53; 95% CI, 0.35-0.81; P = .001 by 1-sided log-rank test for time to recurrence). Fifteen patients had tumors that progressed to muscle invasion (5 in the gemcitabine group and 10 in the saline group; P = .22 by 1-sided log-rank test) and 42 died of any cause (17 in the gemcitabine group and 25 in the saline group; P = .12 by 1-sided log-rank test). There were no grade 4 or 5 adverse events and no significant differences in adverse events of grade 3 or lower. CONCLUSIONS AND RELEVANCE: Among patients with suspected low-grade non-muscle-invasive urothelial cancer, immediate postresection intravesical instillation of gemcitabine, compared with instillation of saline, significantly reduced the risk of recurrence over a median of 4.0 years. These findings support using this therapy, but further research is needed to compare gemcitabine with other intravesical agents. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00445601.
引用
- Messing EM, Tangen CM, Lerner SP, et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018. PMID: 29801011. doi:10.1001/jama.2018.4657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。